Trial Profile
Phase II Trial of Pembrolizumab and Radiotherapy in Cutaneous T-cell Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Cutaneous T-cell lymphoma; Mycosis fungoides; Sezary syndrome
- Focus Therapeutic Use
- Acronyms PORT
- 05 Dec 2023 Planned End Date changed from 1 May 2025 to 1 Sep 2024.
- 12 May 2023 Status changed from recruiting to active, no longer recruiting.
- 09 May 2023 Planned End Date changed from 1 Jan 2025 to 1 May 2025.